Current concepts and controversies in the treatment of alcoholic hepatitis

World Journal of Gastroenterology

Volumn 12, Issue 43, 2006, Pages 6909-6921

  Rongey, Catherine ^a   Kaplowitz, Neil ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Alcoholic hepatitis; Biopsy; Glucocorticoid; Scoring system; Treatment

Indexed keywords

ALCOHOL; ANABOLIC AGENT; COLCHICINE; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; METHYLPREDNISOLONE; OXANDROLONE; PENTOXIFYLLINE; PLACEBO; PREDNISOLONE; PREDNISONE; PROPYLTHIOURACIL; S ADENOSYLMETHIONINE;

ALCOHOL LIVER DISEASE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG FATALITY; DRUG INDICATION; DRUG MECHANISM; DRUG WITHDRAWAL; EDITORIAL; GASTROINTESTINAL HEMORRHAGE; HEPATORENAL SYNDROME; HUMAN; INFECTION; LIVER BIOPSY; MEDICAL RESEARCH; META ANALYSIS; MYCOSIS; NONHUMAN; NUTRITIONAL SUPPORT; PATHOGENESIS; SCORING SYSTEM; SYSTEMATIC REVIEW;

EID: 33751531509     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i43.6909     Document Type: Editorial

References (135)

1. Alcohol-attributable deaths and years of potential life lost-United States, 2001. MMWR Morb Mortal Wkly Rep 2004; 53: 866-870
2. Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology 2002; 36: 227-242
3. Rehm J, Room R, Monteiro M, Gmel G, Graham K, Rehn N, Sempos CT, Jernigan D. Alcohol as a risk factor for global burden of disease. Eur Addict Res 2003; 9: 157-164
4. O'Shea RS, McCullough AJ. Treatment of alcoholic hepatitis. Clin Liver Dis 2005; 9: 103-134
5. Mathurin P. Corticosteroids for alcoholic hepatitis - what's next? J Hepatol 2005; 43: 526-533
6. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 1999; 19: 205-219
7. Hansen J, Cherwitz DL, Allen JI. The role of tumor necrosis factor-alpha in acute endotoxin-induced hepatotoxicity in ethanol-fed rats. Hepatology 1994; 20: 461-474
8. Child III CG, Surgery and portal hypertension. Child III CG, editor. The Liver and Portal Hypertension. Philadelphia: Saunders;1964: 50
9. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649
10. Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, Poulsen H, Tygstrup N. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 1984; 4: 430-435
11. Sarin SK, Chari S, Sundaram KR, Ahuja RK, Anand BS, Broor SL. Young v adult cirrhotics: a prospective, comparative analysis of the clinical profile, natural course and survival. Gut 1988; 29: 101-107
12. Forman LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Mayo End-stage Liver Disease. Hepatology 2001; 33: 473-475
13. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75: 193-199
14. Carithers RL Jr, Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989; 110: 685-690
15. Ramond MJ, Poynard T, Rueff B, Mathurin P, Theodore C, Chaput JC, Benhamou JP. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 1992; 326: 507-512
16. Forrest EH, Evans CD, Stewart S, Phillips M, Oo YH, McAvoy NC, Fisher NC, Singhal S, Brind A, Haydon G, O'Grady J, Day CP, Hayes PC, Murray LS, Morris AJ. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005; 54: 1174-1179
17. Kulkarni K, Tran T, Medrano M, Yoffe B, Goodgame R. The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol 2004; 38: 453-459
18. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871
19. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470
20. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40: 897-903
21. Sheth M, Riggs M, Patel T. Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol 2002; 2: 2
22. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, Malinchoc M, Kamath PS, Shah V. MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology 2005; 41: 353-358
23. Srikureja W, Kyulo NL, Runyon BA, Hu KQ. MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol 2005; 42: 700-706
24. Forrest EH. Prognostic evaluation of alcoholic hepatitis. J Hepatol 2005; 43: 738-739
25. Tilg H, Kaser A. Predicting mortality by the Glasgow alcoholic hepatitis score: the long awaited progress? Gut 2005; 54: 1057-1059
26. Mallory F. Cirrhosis of this liver. Five differnt types of lesions from which it may arise. Bull Johns Hopkins Hospital 911; 22: 69-74
27. Lefkowitch JH. Morphology of alcoholic liver disease. Clin Liver Dis 2005; 9: 37-53
28. Helman RA, Temko MH, Nye SW, Fallon HJ. Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med 1971; 74: 311-321
29. Bories P, Guedj JY, Mirouze D, Yousfi A, Michel H. Treatment of acute alcoholic hepatitis with prednisolone. 45 patients. Presse Med 1987; 16: 769-772
30. Shumaker JB, Resnick RH, Galambos JT, Makopour H, Iber FL. A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. Am J Gastroenterol 1978; 69: 443-449
31. Campra JL, Hamlin EM Jr, Kirshbaum RJ, Olivier M, Redeker AG, Reynolds TB. Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Ann Intern Med 1973; 79: 625-631
32. Duvoux C, Radier C, Roudot-Thoraval F, Maille F, Anglade MC, Van Nhieu JT, Rosa I, Hospitel S, Abd-Alsamad I, Sitruk V, Seror O, Ziol M, Blondon H, Dhumeaux D, Richardet JP. Low-grade steatosis and major changes in portal flow as new prognostic factors in steroid-treated alcoholic hepatitis. Hepatology 2004; 40: 1370-1378
33. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989; 111: 473-478
34. Sougioultzis S, Dalakas E, Hayes PC, Plevris JN. Alcoholic hepatitis: from pathogenesis to treatment. Curr Med Res Opin 2005; 21: 1337-1346
35. Caldwell SH, Jeffers LJ, Ditomaso A, Millar A, Clark RM, Rabassa A, Reddy KR, De Medina M, Schiff ER. Antibody to hepatitis C is common among patients with alcoholic liver disease with and without risk factors. Am J Gastroenterol 1991; 86: 1219-1223
36. Rosman AS, Waraich A, Galvin K, Casiano J, Paronetto F, Lieber CS. Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Am J Gastroenterol 1996; 91: 498-505
37. Mendenhall CL, Seeff L, Diehl AM, Ghosn SJ, French SW, Gartside PS, Rouster SD, Buskell-Bales Z, Grossman CJ, Roselle GA. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119). Hepatology 1991; 14: 581-589
38. Mendenhall CL, Moritz T, Rouster S, Roselle G, Polito A, Quan S, DiNelle RK. Epidemiology of hepatitis C among veterans with alcoholic liver disease. The VA Cooperative Study Group 275. Am J Gastroenterol 1993; 88: 1022-1026
39. Orrego H, Blake JE, Blendis LM, Medline A. Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology 1987; 92: 208-214
40. Levitsky J, Mailliard ME. Diagnosis and therapy of alcoholic liver disease. Semin Liver Dis 2004; 24: 233-247
41. Van Waes L, Lieber CS. Early perivenular sclerosis in alcoholic fatty liver: an index of progressive liver injury. Gastroenterology 1977; 73: 646-650
42. Worner TM, Lieber CS. Perivenular fibrosis as precursor lesion of cirrhosis. JAMA 1985; 254: 627-630
43. Teli MR, Day CP, Burt AD, Bennett MK, James OF. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346: 987-990
44. Wells R. Prednisolone and testosterone propionate in cirrhosis of the liver. A controlled trial. Lancet 1960; 2: 1416-1419
45. Spahr L, Rubbia-Brandt L, Pugin J, Giostra E, Frossard JL, Borisch B, Hadengue A. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J Hepatol 2001; 35: 582-589
46. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12
47. Moher D, Jadad AR, Nichol G, Penman M, Tugwell P, Walsh S. Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials 1995; 16: 62-73
48. Mendenhall CL, Anderson S, Garcia-Pont P, Goldberg S, Kiernan T, Seeff LB, Sorrell M, Tamburro C, Weesner R, Zetterman R. Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med 1984; 311: 1464-1470
49. Lesesne HR, Bozymski EM, Fallon HJ. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology 1978; 74: 169-173
50. Khan KS, Daya S, Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996; 156: 661-666
51. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-613
52. Blitzer BL, Mutchnick MG, Joshi PH, Phillips MM, Fessel JM, Conn HO. Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis 1977; 22: 477-484
53. Theodossi A, Eddleston AL, Williams R. Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut 1982; 23: 75-79
54. Cabr inverted question marke E, Rodr inverted question markiguez-Iglesias P, Caballer inverted question markia J, Quer JC, S inverted question markanchez-Lombrana JL, Par inverted question markes A, Papo M, Planas R, Gassull MA. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000; 32: 36-42
55. Imperiale TF, McCullough AJ. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 1990; 113: 299-307
56. Christensen E, Gluud C. Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut 1995; 37: 113-118
57. Mathurin P, Mendenhall CL, Carithers RL Jr, Ramond MJ, Maddrey WC, Garstide P, Rueff B, Naveau S, Chaput JC, Poynard T. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002; 36: 480-487
58. Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, Benhamou JP, Chaput JC, Rueff B, Poynard T. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology 1996; 110: 1847-1853
59. Mathurin P, Abdelnour M, Ramond MJ, Carbonell N, Fartoux L, Serfaty L, Valla D, Poupon R, Chaput JC, Naveau S. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 2003; 38: 1363-1369
60. Gluud C, Dejgaard A, Clemmensen I. Plasma fibronectin concentrations in patients with liver diseases. Scand J Clin Lab Invest 1983; 43: 533-537
61. Gluud C, Christoffersen P, Eriksen J, Wantzin P, Knudsen BB. No effect of long-term oral testosterone treatment on liver morphology in men with alcoholic cirrhosis. Am J Gastroenterol 1987; 82: 660-664
62. Kishimoto Y, Yamamoto T, Kato S, Wakushima T, Hirayama C. Gonadal function in male patients with alcoholic and non-alcoholic liver disease. Jpn J Med 1987; 26: 41-15
63. Hall KKV. Histological changes produced by castration and by sex hormones in the adrenals of normal and of castrated male rats. Nature 1937; 140: 318
64. Rosenak B, Moser R, Kilgore B. Treatment of cirrhosis of the liver with testosterone propionate. Gastroenterology 1947; 9: 695-704
65. Rambaldi A, Iaquinto G, Gluud C. Anabolic-androgenic steroids for alcoholic liver disease. Cochrane Database Syst Rev 2003; CD003045
66. Goldberg SJ, Mendenhall CL, Connell AM, Chedid A. "Nonalcoholic" chronic hepatitis in the alcoholic. Gastroenterology 1977; 72: 598-604
67. Bonkovsky HL, Fiellin DA, Smith GS, Slaker DP, Simon D, Galambos JT. A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. I. Short-term effects on liver function. Am J Gastroenterol 1991; 86: 1200-1208
68. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 434-438
69. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, Schiff ER, McClain CJ, Marsano LS, Allen JI. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology 1993; 17: 564-576
70. Shirin H, Bruck R, Aeed H, Frenkel D, Kenet G, Zaidel L, Avni Y, Halpern Z, Hershkoviz R. Pentoxifylline prevents concanavalin A-induced hepatitis by reducing tumor necrosis factor alpha levels and inhibiting adhesion of T lymphocytes to extracellular matrix. J Hepatol 1998; 29: 60-67
71. Bird GL, Sheron N, Goka AK, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990; 112: 917-920
72. Felver ME, Mezey E, McGuire M, Mitchell MC, Herlong HF, Veech GA, Veech RL. Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res 1990; 14: 255-259
73. McHutchison JG, Draguesku RB. Pentoxifylline may prevent renal impairment (hepatorenal syndrome) in severe acute alcoholic hepatitis. Hepatology 1991; 14: 96A
74. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000; 119: 1637-1648
75. McAvoy NC, Forrest EH, Hayes PC. The glasgow alcoholic hepatitis score and the effect of pentoxifylline in alcoholic hepatitis. Gut 2005; 54 (Supplement 2): 44A
76. Spahr L, Rubbia-Brandt L, Frossard JL, Giostra E, Rougemont AL, Pugin J, Fischer M, Egger H, Hadengue A. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 2002; 37: 448-455
77. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, Ludwiczek O, Shawcross D, Zoller H, Alisa A, Mookerjee RP, Graziadei I, Datz C, Trauner M, Schuppan D, Obrist P, Vogel W, Williams R. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003; 38: 419-425
78. Mookerjee RP, Tilg H, Williams R, Jalan R. Infliximab and alcoholic hepatitis. Hepatology 2004; 40: 499-500; author reply 500-501
79. Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA, Davion T, Oberti F, Broet P, Emilie D. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 1390-1397
80. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405
81. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343: 1594-1602
82. Mookerjee RP, Tilg H, Williams R, Jalan R. Infliximab and alcoholic hepatitis. Hepatology 2004; 40: 499-500; author reply 500-501
83. Menon KV, Stadheim L, Kamath PS, Wiesner RH, Gores GJ, Peine CJ, Shah V. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004; 99: 255-260
84. Anonymous. Remicade(infliximab) for IV injection. 2005 Available from: www.fda.gov/medwatch/SAFETY/2005/may05.htm
85. Patek AJ Jr. Alcohol, malnutrition, and alcoholic cirrhosis. Am J Clin Nutr 1979; 32: 1304-1312
86. Linscheer WG, Patterson JF, Moore EW, Clermont RJ, Robins SJ, Chalmers TC. Medium and long chain fat absorption in patients with cirrhosis. J Clin Invest 1966; 45: 1317-1325
87. Halsted CH. Nutrition and alcoholic liver disease. Semin Liver Dis 2004; 24: 289-304
88. Simon D, Galambos JT. A randomized controlled study of peripheral parenteral nutrition in moderate and severe alcoholic hepatitis. J Hepatol 1988; 7: 200-207
89. Mezey E, Caballeria J, Mitchell MC, Pares A, Herlong HF, Rodes J. Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: a randomized controlled trial. Hepatology 1991; 14: 1090-1096
90. James LP, Farrar HC, Darville TL, Sullivan JE, Givens TG, Kearns GL, Wasserman GS, Simpson PM, Hinson JA. Elevation of serum interleukin 8 levels in acetaminophen overdose in children and adolescents. Clin Pharmacol Ther 2001; 70: 280-286
91. Mendenhall CL, Anderson S, Weesner RE, Goldberg SJ, Crolic KA. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984; 76: 211-222
92. Mendenhall C, Roselle GA, Gartside P, Moritz T. Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res 1995; 19: 635-641
93. Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, Schiff ER, McClain CJ, Marsano LS, Allen JI. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. JPEN J Parenter Enteral Nutr 1995; 19: 258-265
94. Mendenhall CL, Tosch T, Weesner RE, Garcia-Pont P, Goldberg SJ, Kiernan T, Seeff LB, Sorell M, Tamburro C, Zetterman R. VA cooperative study on alcoholic hepatitis. II: Prognostic significance of protein-calorie malnutrition. Am J Clin Nutr 1986; 43: 213-218
95. Mendenhall C, Bongiovanni G, Goldberg S, Miller B, Moore J, Rouster S, Schneider D, Tamburro C, Tosch T, Weesner R. VA Cooperative Study on Alcoholic Hepatitis. III: Changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy. JPEN J Parenter Enteral Nutr 1985; 9: 590-596
96. Mata JM, Kershenobich D, Villarreal E, Rojkind M. Serum free proline and free hydroxyproline in patients with chronic liver disease. Gastroenterology 1975; 68: 1265-1269
97. Trinchet JC, Beaugrand M, Callard P, Hartmann DJ, Gotheil C, Nusgens BV, Lapiere CM, Ferrier JP. Treatment of alcoholic hepatitis with colchicine. Results of a randomized double blind trial. Gastroenterol Clin Biol 1989; 13: 551-555
98. Akriviadis EA, Steindel H, Pinto PC, Fong TL, Kanel G, Reynolds TB, Gupta S. Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology 1990; 99: 811-818
99. Rambaldi A, Gluud C. Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev 2005; CD002148
100. Morgan TR, Weiss DG, Nemchausky B, Schiff ER, Anand B, Simon F, Kidao J, Cecil B, Mendenhall CL, Nelson D, Lieber C, Pedrosa M, Jeffers L, Bloor J, Lumeng L, Marsano L, McClain C, Mishra G, Myers B, Leo M, Ponomarenko Y, Taylor D, Chedid A, French S, Kanel G, Murray N, Pinto P, Fong TL, Sather MR. Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology 2005; 128: 882-890
101. Lieber CS. Role of S-adenosyl-L-methionine in the treatment of liver diseases. J Hepatol 1999; 30: 1155-1159
102. Lieber CS. S-adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr 2002; 76: 1183S-1187S
103. Lee TD, Sadda MR, Mendler MH, Bottiglieri T, Kanel G, Mato JM, Lu SC. Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. Alcohol Clin Exp Res 2004; 28: 173-181
104. Garcia-Ruiz C, Morales A, Colell A, Ballesta A, Rodes J, Kaplowitz N, Fernandez-Checa JC. Feeding S-adenosyl-L-methionine attenuates both ethanol-induced depletion of mitochondrial glutathione and mitochondrial dysfunction in periportal and perivenous rat hepatocytes. Hepatology 1995; 21: 207-214
105. Lieber CS, Casini A, DeCarli LM, Kim CI, Lowe N, Sasaki R, Leo MA. S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. Hepatology 1990; 11: 165-172
106. Gasso M, Rubio M, Varela G, Cabre M, Caballeria J, Alonso E, Deulofem R, Camps J, Gimenez A, Pajares M, Pares A, Mato JM, Rodes J. Effects of S-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis. J Hepatol 1996; 25: 200-205
107. Bray GP, Tredger JM, Williams R. S-adenosylmethionine protects against acetaminophen hepatotoxicity in two mouse models. Hepatology 1992; 15: 297-301
108. Rambaldi A, Gluud C. S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev 2001; CD002235
109. Mato JM, Camara J, Fernandez de Paz J, Caballeria L, Coll S, Caballero A, Garcia-Buey L, Beltran J, Benita V, Caballeria J, Sola R, Moreno-Otero R, Barrao F, Martin-Duce A, Correa JA, Pares A, Barrao E, Garcia-Magaz I, Puerta JL, Moreno J, Boissard G, Ortiz P, Rodes J. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30: 1081-1089
110. Israel Y, Kalant H, Orrego H, Khanna JM, Videla L, Phillips JM. Experimental alcohol-induced hepatic necrosis: suppression by propylthiouracil. Proc Natl Acad Sci USA 1975; 72: 1137-1141
111. Rodriguez-Rodriguez E, Gonzalez-Reimers E, Santolaria-Fernandez F, Milena-Abril A, Rodriguez-Moreno F, Oramas-Rodriguez J, Martinez-Riera A. Cytokine levels in acute alcoholic hepatitis: a sequential study. Drug Alcohol Depend 1995; 39: 23-27
112. Iturriaga H, Ugarte G, Israel Y. Hepatic vein oxygenation, liver blood flow, and the rate of ethanol metabolism in recently abstinent alcoholic patients. Eur J Clin Invest 1980; 10: 211-218
113. Rambaldi A, Gluud C. Meta-analysis of propylthiouracil for alcoholic liver disease - a Cochrane Hepato-Biliary Group Review. Liver 2001; 21: 398-404
114. Orrego H, Kalant H, Israel Y, Blake J, Medline A, Rankin JG, Armstrong A, Kapur B. Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology 1979; 76: 105-115
115. Serrano-Cancino H. Treatment of severe alcoholic hepatitis with propylthiouracil (PTU). Am J Gastroenterol 1981; 76: 194
116. Halle P, Pare P, Kaptein E, Kanel G, Redeker AG, Reynolds TB. Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology 1982; 82: 925-931
117. Orrego H, Blake JE, Blendis LM, Compton KV, Israel Y. Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med 1987; 317: 1421-1427
118. Pierrugues R. Short-term therapy with propylthiouracile (PTU) for alcoholic hepatitis (AH). A clinical, biochemical and histological randomized trial about 29 patients. J Hepatol 1989; 9: S72
119. Sogni P, Hadengue A, Moreau R, Le Moine O, Soupison T, Oberti F, Farinotti R, Lebrec D. Acute effects of propylthiouracil on hemodynamics and oxygen content in patients with alcoholic cirrhosis. J Hepatol 1997; 26: 628-633
120. Mihas AA, Holley P, Koff RS, Hirschowitz BI. Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil. Gastroenterology 1976; 70: 770-774
121. Limaye A, Ruffolo PR. Propylthiouracil-induced fatal hepatic necrosis. Am J Gastroenterol 1987; 82: 152-154
122. Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, Escribano AA. Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother 2003; 37: 224-228
123. Deidiker R, deMello DE. Propylthiouracil-induced fulminant hepatitis: case report and review of the literature. Pediatr Pathol Lab Med 1996; 16: 845-852
124. Ichiki Y, Akahoshi M, Yamashita N, Morita C, Maruyama T, Horiuchi T, Hayashida K, Ishibashi H, Niho Y. Propylthiouracil-induced severe hepatitis: a case report and review of the literature. J Gastroenterol 1998; 33: 747-750
125. Dai WX, Zhang JD, Zhan SW, Xu BZ, Jin H, Yao Y, Xin WC, Bai Y. Retrospective analysis of 18 cases of antithyroid drug (ATD)-induced agranulocytosis. Endocr J 2002; 49: 29-33
126. Porter HP, Simon FR, Pope CE 2nd, Volwiler W, Fenster LF. Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. N Engl J Med 1971; 284: 1350-1355
127. Depew W, Boyer T, Omata M, Redeker A, Reynolds T. Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology 1980; 78: 524-529
128. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, Ludwiczek O, Shawcross D, Zoller H, Alisa A, Mookerjee RP, Graziadei I, Datz C, Trauner M, Schuppan D, Obrist P, Vogel W, Williams R. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003; 38: 419-425
129. Galambos JT, Hersh T, Fulenwider JT, Ansley JD, Rudman D. Hyperalimentation in alcoholic hepatitis. Am J Gastroenterol 1979; 72: 535-541
130. Nasrallah SM, Galambos JT. Aminoacid therapy of alcoholic hepatitis. Lancet 1980; 2: 1276-1277
131. Diehl AM, Boitnott JK, Herlong HF, Potter JJ, Van Duyn MA, Chandler E, Mezey E. Effect of parenteral amino acid supplementation in alcoholic hepatitis. Hepatology 1985; 5: 57-63
132. Calvey H, Davis M, Williams R. Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. J Hepatol 1985; 1: 141-151
133. Soberon S, Pauley MP, Duplantier R, Fan A, Halsted CH. Metabolic effects of enteral formula feeding in alcoholic hepatitis. Hepatology 1987; 7: 1204-1209
134. Cabr inverted question marke E, Rodr inverted question markiquez-Iglesias P, Caballer inverted question markia J, Quer JC, S inverted question markanchez-Lombrana JL, Par inverted question markes A, Papo M, Planas R, Gassull MA. Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology 2000; 32: 36-42
135. Alvarez MA, Cabre E, Lorenzo-Zuniga V, Montoliu S, Planas R, Gassull MA. Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study. Eur J Gastroenterol Hepatol 2004; 16: 1375-1380